Congruence Therapeutics

Congruence Therapeutics

  • Founded: 2021
  • Location: Montréal, QC
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Genetic metabolic disease
  • Drug types: RAR, GEN, NEU, ONC
  • Lead product: Undisclosed
  • Product link:
  • Funding: $15M A Mar 2023; $50M A Feb 2022
  • Investors: Thrive Venture Fund, Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc

job board

Short description:

Computational platform for small molecule discovery targeting protein misfolding diseases

Drug notes:

4 additional undisclosed programs RD genetic metabolic disease, rare genetic disease/neurological disease, multiple cancers, undisclosed

Long description:

Congruence Therapeutics is working at the interface of computational and experimental drug discovery to go from protein topology to treatments. Proteins are not not static: they are dynamic, undergoing conformational transformations and interacting with the surrounding biological environment. Mutations in proteins can alter these dynamics offering new potential drug binding sites. Using protein dynamics, biophysics, machine learning and computational chemistry, Congruence has built their drug discovery engine, RevenirTM, which captures the biophysical changes caused by mutations in proteins. The RevenirTM engine offers Congruence the opportunity to build a pipeline of drugs for various indications such as genetic metabolic disorders.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy